Sign up to save your podcasts
Or
Share IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
IgAN Management Into Practice: Evolving Guidelines & Targeted Therapies
CME credits: 0.25
Valid until: 19-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/
Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria treatment goal of <0.3 g/d and the use of combination therapy targeting immune modulation and CKD management. In addition, they highlight the use of Nefecon, a disease-modifying therapy now recommended as a first-line treatment where approved.
=
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 19-11-2026
Claim your CME credit at https://reachmd.com/programs/cme/igan-management-into-practice-evolving-guidelines-targeted-therapies/37238/
Dr. Jürgen Floege, co-chair of the KDIGO Work Group, and Dr. Jörg Latus review the updated KDIGO 2025 guidelines for managing immunoglobulin A nephropathy (IgAN) and IgA vasculitis (IgAV), which emphasize diagnostic criteria, proteinuria-based treatment thresholds, and revised therapeutic goals. The discussion focuses on the new KDIGO proteinuria treatment goal of <0.3 g/d and the use of combination therapy targeting immune modulation and CKD management. In addition, they highlight the use of Nefecon, a disease-modifying therapy now recommended as a first-line treatment where approved.
=